Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
-
New imaging agent shows promise for kidney cancer detection
Diagnosis CompletedThis study tested a new radioactive imaging agent, 68Ga-OncoCAIX, in 20 people with a type of kidney cancer called clear cell renal cell carcinoma. The goal was to see if it is safe and how it spreads in the body. Researchers measured radiation doses to organs and checked for sid…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Diagnosis
Last updated Jun 27, 2026 08:10 UTC
-
New imaging agent shows promise for prostate cancer detection
Diagnosis CompletedThis study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and to measure how much radiation the body receives. The agent helps doctors see where cancer has spread using a special scan.
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC